Modern Vaccines Adjuvants Formulation

18-20 May 2016, Eigtveds Pakhus, Copenhagen, Denmark

  • Increase font size
  • Default font size
  • Decrease font size

Posters

Final Conference Programme | Poster Session

Poster 101
‘A live Salmonella gallinarum vaccine candidate secreting an adjuvant protein confers enhanced safety and protection against fowl typhoid’
John Hwa Lee
(College of Veterinary Medicine, Chonbuk National University, Iksan, South Korea)

Poster 102
‘Evaluation of Salmonella gallinarum ghost formulated with montanidetm ISA70 VG-adjuvant as a vaccine against fowl typhoid’
John Hwa Lee
(College of Veterinary Medicine, Chonbuk National University, Iksan, South Korea)

Poster 103
‘Recombinant lipoimmunogen-based cancer immunotherapy’
Shih-Jen Liu and Chih-Hsiang Leng
(National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Miaoli, Taiwan)

Poster 104
‘Recombinant lipoprotein induces broad spectrum of cellular and humoral immune responses without exogenous adjuvant formulation’
Chen-Yi Chiang 1, Shih-Jen Liu 1,2, Chun-Hsiang Hsieh 1, Mei-Yu Chen 1, Jy-Ping Tsai 1, Hsueh-Hung Liu 1, I-Hua Chen 1, Pele Chong 1,2, Chih-Hsiang Leng 1,2 and Hsin-Wei Chen 2
(1 National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Miaoli, Taiwan)

Poster 105
‘Immune response in mice and chickens using novel phosphazene adjuvants’
J. V. van den Hurk, V. Gerdts, G. Mutwiri, W. Koester, S. Strom, D. Dent, S. Lam and S. Attah-Poku
(VIDO-Intervac, University of Saskatchewan, Saskatoon, Canada)

Poster 106
‘Manufacturing of PLGA nanoparticles as vaccine adjuvants by using microfluidics’
Carla B. Roces Rodriguez 1, Dennis Christensen 2 and Yvonne Perrie 1
(1 University of Strathclyde, Glasgow, UK; 2 Statens Serum Institut, Copenhagen, Denmark)

Poster 107
‘Advax enhances different types of adaptive immune response dependent upon antigen properties’
Masayuki Hayashi 1,2,3, Taiki Aoshi 1,3, Cevayir Coban 4, Nikolai Petrovsky 5 and Ken J Ishii 1,3
(1 National Institute of Biomedical Innovation, Health and Nutrition (NIBIOHN), Japan; 2 Mitsubishi Tanabe Pharma Corporation, Japan; 3 Osaka University , Osaka, Japan; 4Laboratory of Malaria Immunology, WPI Immunology Frontier Research Center, Osaka University, Osaka, Japan;5Vaxine Pty Ltd, Australia)

Poster 108
‘Novel carbohydrate monosulphate ester (CMS) adjuvant’
Luuk Hilgers 1, Jeffrey Bajramovic 2, Peter Paul Platenburg 1 and Han van den Bosch 1
(1 LiteVax BV, Oss, the Netherlands; 2 BPRC, Rijswijk, The Netherlands)

Poster 109
‘Feasibility of single-shot vaccines with a more effective adjuvant’
Peter Paul Platenburg, Luuk Hilgers and Han van den Bosch
(LiteVax BV, Oss, The Netherlands)

Poster 110
‘Intranasal hydroxypropyl-β-cyclodextrin (HP-β-CD)-adjuvanted influenza vaccine protects against sub-heterologous virus infection’
Takato Kusakabe 1,2, Etsushi Kuroda 2 and Ken J Ishii 1,2
(1 Laboratory of Adjuvant Innovation, National Institute of Biomedical Innovation; 2 WPIImmunology Frontier Research Center, Osaka University, Osaka, Japan)

Poster 111
‘Overcoming the cold-chain distribution hurdle: Development of a lyophilized thermostable single vial adjuvanted vaccine against tuberculosis’
Michelle Y. Chan, Alicia M. Schwartz, Dawn M. Fedor, Quinton M. Dowling, Elyse A. Beebe, Liam Kapilow-Cohen, Thomas S. Vedvick, Mark T. Orr, Christopher B. Fox and Ryan M. Kramer (Infectious Disease Research Institute (IDRI), Seattle, Washington, USA)

Poster 112
‘MicroScale Thermophoresis: Interaction analysis and beyond’
Teresia Hallström, Moran Jerabek-Willemsen, Timon André, Randy Wanner, Heide Marie Roth, Stefan Duhr, Philipp Baaske and Dennis Breitsprecher
(Nanotemper Technologies GmbH, Munich, Germany)

Poster 113
‘Adjuvanting a viral vectored vaccine against pre-erythrocytic malaria: modulation of CD8 T cell responses and correlates of protection’
Anita Milicic 1, Christine Rollier 2, Choon Kit Tang 1, Karolis Bauza 1, Rhea Longley 3, Adrian V.S. Hill 1 and Arturo Reyes-Sandoval 4
(1 The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK; 2 Oxford Vaccine Group, University of Oxford and the NIHR Oxford Biomedical Research Centre, Churchill Hospital, Oxford, UK; 3 Population Health and Immunity, Walter & Eliza Hall Institute, Parkville, Australia and Mahidol Vivax Research Unit (MVRU), Mahidol University, Bangkok, Thailand; 4 The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK)

Poster 114
‘Squalene adjuvant formulation with β-carotene II. Influence of β-carotene on antigenic effectivity of adjuvanted rabies vaccine’
A. Ondrejková, J. Süli, P. Cechvala, M. Prokeš, Z. Benko and R. Ondrejka
(University of Veterinary Medicine and Pharmacy, Košice, Slovak Republic)

Poster 115
‘Squalene adjuvant formulation with β-carotene I. Stability characteristics’
J. Süli, A. Ondrejková, J. Harvanová and R. Ondrejka
(University of Veterinary Medicine and Pharmacy, Košice, Slovak Republic)

Poster 116
‘Lipoid adjuvant formulations for mucosal antirabies immunisation’
R. Ondrejka, J. Süli and A. Ondrejková
(University of Veterinary Medicine and Pharmacy, Košice, Slovak Republic)

Poster 117
‘Solution to terminal sterilization of nanoemulsion adjuvants by combining high shear processing and filtration’
K. Jandrasitz 1, S. Mesite 1, Y. Su 1, R. Turmell 2, M. Folmsbee 2 and K. Marion 2
(1 Microfluidics International Corporation, Westwood, Masachusetts, USA; 2 Pall Life Sciences, Port Washington, New York, USA)

Poster 118
‘Novel liposomal formulation for in vivo expansion of CD8 T cells against whole protein antigens’
Jackson K. Eby, Adrienne V. Li, Yunwei Sun and Peter C. DeMuth (Vedantra Pharmaceuticals, Inc., Cambridge, Massachusetts, USA)

Poster 119
‘Nanoformulation of synergistic TLR ligands to enhance protective immunity against Entamoeba histolytica’
Mayuresh M. Abhyankar 1, Zannatun Noor 1, Lisa Barroso 2, David Lyerly 2, Christopher B. Fox 3 and William A. Petri, Jr. 1 ( 1 University of Virginia, Charlottesville, Virginia, USA; 2 TechLab, Inc., Blacksburg, Virginia, USA; 3 Infectious Disease Research Institute, Seattle, Washington, USA)

Poster 120
‘Systemic vaccination with a tuberculosis subunit vaccine in presence of retinoic acid leads to a better containment of the bacterial load in the lung’
Antonella Riccomi, Valentina Gesa, Elisa Cirelli, Else Marie Agger, Giovanni Piccaro, Carla Palma and Silvia Vendetti (Istituto Superiore di Sanità, Rome, Italy; Statens Serum Institute, Copenhagen, Denmark)

 

MVAF 2016 Delegates

Login details will be supplied after you have registered for the event.


MVAF 2016 Sponsors

  • Brenntag
  • hVIVO
  • CureVac
  • NatureGeneTherapy.com
  • Sanofi Pasteur
  • IntraVacc
  • Aldevron
  • Inovio
  • Bioaster
  • EVI
  • Vaxart
  • Mucosis
  • IDRI
  • DNAvaccine.com
  • Pfizer
  • NanoTemper Technologies
  • Seppic

MVAF 2016 Downloads

MVAF 2016 Leaflet

MVAF 2016 Mailing List

Name
E-mail Address
What is 3+2-1?